Extracts from RM research paper into ksx.KarmelSonix has brought...

Extracts from RM research paper into ksx.
KarmelSonix has brought together a skilled and experienced International comercial and scientific team.
RM research considers that the home based wheezometer can be fast tracked to commercialisation over the next 12 months.The company is also currently clinically validating the WIM-PC , a device for assesing asthma in clinics.
An MOU FOR COMMERCIAL distribution has been entered into with nSpire inc a MAJOR US/UK international respiratory devices company.
KSX has bought in an expanded develpment team of 5 people to ensure that all development time frames are achieved and has also established an electronic-acoustic lab equipped with state of the art medical device equipment and hardware.
The WIM-PC technology can be used in allergy and asthma clinics, primary care physicians, pedriaticians and pulmanary function testing labs.
First sales of the wheezometer , a stand alone miniature are likely to commence by the middle of next year. The product is expected to be rolled out through the OTC market GLOBALLY. RM research considers nSpire has sound distrubution capacity throughout North America and Europe.
The Burgeoning market in the US which affects 16% of the population exceeds US$15 Billion.
KarmelSonix aims to be a leader in Acoustic Asthma management to the clinical market.And the WIM-PC has recieved strong feedback from LEADING International clinicians.A series of clinical studies are bieng conducted in the USA, Europe,UK , Israel and Australia and we consider that these trials have the potential to generate a SUBSTANTIAL amount of buy-in interest.
The earnings model provide for strong margins and net profit margin NPM.
KSX aims to achieve margins of 65% of the selling price of the WIM-PC.It is also expected that the gross margin for the personal wheezometer will be in the order of 70%.
In addition it is expected that KSX willalso recieve licensing, sub-licensing fees and further revenues from sale of consumables and other services..
New management appointments have strengthened and broadened the management team.Appointements of Brad Sheehan and Mr Israel Tal will add significant scope to regulatory and global distribution activities.
Israel Tal the corporate VP of sales was prior to his appointment the Director of Business Development at SHL Telemedicine, a public healthcare company which specialises in home monitoring of cardiac patients together with sales of telemedicine systems.
Brad Sheehan, the Asia Pacific general manager joins Karmel after a 5 year tenure at biotechnology company Clinical Cell Culture as vice president of quality and regulatory affairs.
The company now through the recent placement has over $A5.5 million to start the roll out of this cutting edge technology and as they have stated in the announcement "expects to be in a position to provide a further update on activities, including commercial progress over the course of the next few weeks".
phil.